MARKET

INVA

INVA

Innoviva
NASDAQ
22.31
+0.41
+1.87%
After Hours: 22.31 0 0.00% 16:23 07/02 EDT
OPEN
22.05
PREV CLOSE
21.90
HIGH
22.32
LOW
21.70
VOLUME
655.04K
TURNOVER
--
52 WEEK HIGH
25.15
52 WEEK LOW
16.52
MARKET CAP
1.65B
P/E (TTM)
3.696
1D
5D
1M
3M
1Y
5Y
1D
Is Innoviva (INVA) Trading Index Membership for a Deeper Bet on Nortiva Bio’s LYNX Platform?
Simply Wall St · 1d ago
Basilea publishes investor presentation on anti-infectives strategy, pipeline focus
PUBT · 4d ago
Weekly Report: what happened at INVA last week (0622-0626)?
Weekly Report · 5d ago
Is Innoviva (INVA) Undervalued After Nortiva Bio Launch And XACDURO Deal?
Simply Wall St · 6d ago
How Investors Are Reacting To Innoviva (INVA) Expanding Drug Delivery Tech And XACDURO Global Partnership
Simply Wall St · 06/26 12:22
Armata Pharma amends 8-K to disclose director Daniel Gilmer committee assignment
PUBT · 06/24 20:20
Innoviva: Buy Rating Reiterated as LYNX Platform Strengths Support Unchanged $42 Price Target
TipRanks · 06/23 10:25
Innoviva Is Maintained at Buy by BTIG
Dow Jones · 06/22 21:20
More
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

Webull offers Innoviva Inc stock information, including NASDAQ: INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.